<!DOCTYPE html>
<html lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta name="description" content="">
    <meta name="author" content="">
    <link rel="shortcut icon" href="">
  	<!--REQUIRED CSS files-->
    <link href="../../css/cchbasics.css" rel="stylesheet">
    <link href="../../css/font-awesome.min.css" rel="stylesheet">
    <link href="../../css/bootstrap.min.css" rel="stylesheet">
   <link href="../../css/cch.css" rel="stylesheet">

    <title>CCH Android Application</title>
  </head>
  <body class="greenback">
      <div class="container dropme ">
		<div class="sticky greenback"  >
		<a href="index.html"><H2><i class="fa fa-home pull-right greenme"></i></H2></a>
		<H4>Intermittent Preventive Treatment (IPTp) with Sulfadoxine-Pyrimethamine (SP) for Malaria Prevention in Pregnant Women</H4>
		</div>
		<br><br>
		<div class="padme row">
		<div class="col-md-6 col-md-offset-3">
					<H5 class="heavy greenme">Target groups for IPTp using SP include:</H5>
					<ul>
						<li>All pregnant women with no signs clinical of malaria whose pregnancies are between 16-36 weeks of gestation</li><br/>
						<li>Women with first or second pregnancies</li><br/>
						<li>Adolescent and young pregnant women (10-24 years)</li><br/>
						<li>Pregnant women with sickle cell disease</li><br/>
						<li>Pregnant women with HIV infection and other immunocompromised states</li><br/>
					</ul>

					<p><br />
					<H5="class heavy">Pregnant women with the following conditions should be exempted from using SP:</H5>
					<ul>
						<li>Women in their 1<sup>st</sup> trimester of pregnancy (first 3 months)</li><br/>
						<li>Women known to have Glucose-6-Phosphate Dehydrogenase (G6PD) enzyme deficiency, either full or partial defect</li><br/>
						<li>Women known to have severe liver disease</li><br/>
						<li>Women with unexplained recurrent jaundice</li><br/>
						<li>Women who are known to be allergic to sulphur-containing drugs or pyrimethamine component</li><br/>
						<li>Women who have received treatment with sulphur-based drugs, e.g. cotrimoxazole within 4 weeks of being seen at the clinic</li><br/>
						<li>Women with HIV/AIDS who have been put on cotrimoxazole for opportunistic infections</li><br/>
						<li>Women with pregnancy beyond 36 weeks (8 months) gestation</li><br/>
						<li>Women breastfeeding</li>
					</ul>
					<H5 class="greenme heavy">Dosage of SP for IPTp:</H5>
					<p>New GHS guidelines indicate that pregnant women should take up to 5 doses of SP for antimalarial prophylaxis. <br/><br/>A single dose compromising 3 tablets of 500 mg sulfadoxine + 25 mg pyrimethamine taken with clean water.<br/><br/>Ensure pregnant clients eat BEFORE taking the drug.<br/> The following is the dosage schedule for SP:</p>
					<ul>
						<li>1<sup>st</sup> dose at 16 wks gestation   The 1st dose should be administered by a midwife, therefore refer clients to the health facility. </li><br/>
						<li>2<sup>nd</sup> dose at least 4 weeks after 1<sup>st</sup> dose</li><br/>
						<li>3<sup>rd</sup> dose at least 4 weeks after 2<sup>nd</sup> dose</li><br/>
						<li>4<sup>th</sup> dose at least 4 weeks after 3<sup>rd</sup> dose</li><br/>
						<li>5<sup>th</sup> dose at least 4 weeks after 4<sup>th</sup> dose</li><br/>
					</ul>

					Note:  The last dose of SP can be administered up to the time of delivery without any safety concerns. 
					Source: WHO 
					<br/>
					<H5 class="greenme heavy">Counselling/Education on Use of SP</H5>

					<ul>
						<li>All pregnant women should be educated and counselled on IPTp using SP on an individual basis prior to drug administration</li><br/>
						<li>Women who receive SP should be educated on the potential adverse effects and what to do when these arise</li><br/>
						<li>Women who refuse IPTp using SP for any reason should NOT be discriminated against, and should be counselled to use ITN</li><br/>
					</ul>	
				</div>

			</div>
		</div><!-- /.container -->


    <!-- Bootstrap core JavaScript
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
</body>
</html>